spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  SPIRIT V 

 HSMN NewsFeed - 20 May 2010
Boston Scientific Announces Schedule for EuroPCR 2010
Devices Interventional Cardiology
 HSMN NewsFeed - 14 Sep 2009
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 31 Aug 2009
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Aug 2009
Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 21 May 2009
Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2009
Boston Scientific Announces Schedule for EuroPCR 2009
Devices Interventional Cardiology
 HSMN NewsFeed - 27 Nov 2007
Abbott to Present Comprehensive Safety and Efficacy Data on XIENCE(TM) V Drug Eluting Stent to FDA Advisory Committee on Nov. 29
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 19 Jul 2007
Abbott Enrolls First Patient in World's First Clinical Trial Designed to Study Drug Eluting Stent Treatment in Women
Devices Interventional Cardiology
 HSMN NewsFeed - 22 May 2007
Abbott Announces Continued Positive Results with XIENCE(TM) V Everolimus Eluting Coronary Stent in SPIRIT Clinical Trials
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Mar 2007
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Superior to TAXUS(R) Stent in SPIRIT III U.S. Pivotal Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Feb 2007
Abbott to Initiate First Study to Evaluate XIENCE(TM) V Everolimus Eluting Coronary Stent System in Treatment of Women With Cardiovascular Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Jan 2007
Private-Label Version of Abbott's XIENCE(TM)V Drug-Eluting Coronary Stent System Launches in Europe
Devices Interventional Cardiology
 HSMN NewsFeed - 3 Oct 2006
Abbott Begins Early International Launch of XIENCE(TM) V Everolimus Eluting Coronary Stent System
Devices Interventional Cardiology
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
SPIRIT V
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.